WEST virginia legislature
2019 Regular session
Introduced
House Bill 2768
By Delegate Rohrbach
[Introduced January 30, 2019; Referred
to the Committee on Prevention and Treatment of Substance Abuse then Health and
Human Resources.]
A BILL to amend and reenact §16-54-1, §16-54-3, §16-54-4, §16-54-5, §16-54-6, §16-54-7, and §16-54-8, of the Code of West Virginia, 1931, as amended, all relating to reducing the use of certain prescription drugs; defining terms; clarifying types of examinations; requiring certain information in a narcotics contract; clarifying that the drug being regulated is a schedule II opioid drug; providing exceptions; and requiring coverage for certain procedures to treat chronic pain.
Be it enacted by the Legislature of West Virginia:
ARTICLE 54. Opioid reduction Act.
As used in this section:
“Acute pain” means a time limited pain caused by a specific disease or injury.
“Chronic pain” means a noncancer, nonend of life pain lasting more than three months or longer than the duration of normal tissue healing.
“Health care practitioner” or “practitioner” means:
(1) A physician licensed
authorized pursuant to the provisions of §30-3-1 et seq. and
§30-14-1 et seq. of this code;
(2) A podiatrist licensed pursuant to the provisions of §30-3-1 et seq. of this code;
(3) A physician assistant with prescriptive authority as set forth in §30-3E-3 of this code;
(4) An advanced practice registered nurse with prescriptive authority as set forth in §30-7-15a of this code;
(5) A dentist licensed pursuant to the provisions of §30-4-1 et seq. of this code; and
(6) An optometrist licensed pursuant to the provisions of §30-8-1 et seq. of this code;
“Insurance provider” means an entity that is regulated under the provisions of §33-6-1 et seq., §33-15-1 et seq., §33-16-1 et seq., and §33-25A-1 et seq. of this code.
“Office” means the Office of Drug Control Policy.
“Pain clinic” means the same as that term is defined in §16-5H-2 of this code.
“Pain specialist” means a practitioner who is board certified in pain management or a related field.
“Schedule II opioid drug” means an opioid drug contained in §60A-2-206 of this code.
“Surgical procedure” means a medical procedure involving an incision with instruments performed to repair damage or arrest disease in a living body.
Prior to issuing a prescription for an opioid a
Schedule II opioid drug, a practitioner shall:
(1) Advise the patient regarding the quantity of the opioid
Schedule II opioid drug and a patient’s option to fill the prescription
in a lesser quantity; and
(2) Inform the patient of the risks associated with the opioid
Schedule II opioid drug prescribed.
§16-54-4. Opioid prescription limitations.
(a) When issuing a prescription for an opioid a Schedule II opioid drug to an adult patient
seeking treatment in an emergency room for outpatient use, a health care
practitioner may not issue a prescription for more than a four-day supply: Provided,
That a prescription for a Schedule II opioid drug issued to an adult
patient in an emergency room for outpatient use is not considered to be an
initial Schedule II opioid prescription.
(b) When issuing a prescription for an opioid a
Schedule II opioid drug to an adult patient seeking treatment in an urgent
care facility setting for outpatient use, a health care practitioner may not
issue a prescription for more than a four-day supply: Provided, That an
additional dosing for up to no more than a seven-day supply may be permitted,
but only if the medical rational for more than a four-day supply is documented
in the medical record.
(c) A health care practitioner may not issue an opioid
an initial Schedule II opioid drug prescription to a minor for more than
a three-day supply and shall discuss with the parent or guardian of the minor
the risks associated with opioid Schedule II opioid drug use and
the reasons why the prescription is necessary.
(d) A dentist or an optometrist may not issue an opioid
a Schedule II opioid drug prescription for more than a three-day supply.
at any time.
(e) A practitioner, other than a dentist or an
optometrist, may not issue an initial opioid Schedule II opioid
drug prescription for more than a seven-day supply. The prescription shall
be for the lowest effective dose which in the medical judgement of the
practitioner would be the best course of treatment for this patient and his or
her condition.
(f) Prior to issuing an initial opioid Schedule
II opioid drug prescription, a practitioner shall:
(1) Take and document the results of a thorough medical history, including the patient’s experience with nonopioid medication, nonpharmacological pain management approaches, and substance abuse history;
(2) Conduct, as appropriate, and document the results of a physical examination. The physical exam should be relevant to the specific diagnosis and course of treatment, and should assess whether the course of treatment would be safe and effective for the patient.
(3) Develop a treatment plan, with particular attention focused on determining the cause of the patient’s pain; and
(4) Access relevant prescription monitoring information under the Controlled Substances Monitoring Program Database.
(g) Notwithstanding any provision of this code or
legislative rule to the contrary, no medication listed as a Schedule II controlled
substance opioid drug as set forth in §60A-2-206 of this code, may
be prescribed by a practitioner for greater than a 30-day supply: Provided,
That two additional prescriptions, each for a 30-day period for a total of a
90-day supply, may be prescribed if the practitioner accesses the West Virginia
Controlled Substances Monitoring Program Database as set forth in §60A-9-1 et
seq. of this code: Provided, however, That the limitations in
this section do not apply to cancer patients, patients receiving hospice care
from a licensed hospice provider, patients receiving palliative care, a patient
who is a resident of a long-term care facility, or a patient receiving medications
that are being prescribed for use in the treatment of substance abuse or opioid
dependence.
(h) A practitioner is required to conduct and document the
results of a physical examination every 90 days for any patient for whom he or
she continues to treat with any Schedule II controlled substance opioid
drug as set forth in §60A-2-206 of this code. The physical exam
should be relevant to the specific diagnosis and course of treatment, and
should assess whether continuing the course of treatment would be safe and
effective for the patient.
(i) A veterinarian licensed pursuant to the provisions of
§30-10-1 et seq. of this code may not issue more than an initial opioid
Schedule II opioid drug prescription for more than a seven-day supply.
The prescription shall be for the lowest effective dose which in the medical
judgment of the veterinarian would be the best course of treatment for this
patient and his or her condition.
(j) A prescription for any opioid drug listed on In
conjunction with the issuance of the third prescription for a Schedule II opioid
drug, as set forth in §60A-2-206 of this code for greater than a
seven-day period shall require the patient to shall execute a
narcotics contract with their prescribing practitioner. The contract shall be
made a part of the patient’s medical record. The narcotics contract is
required to provide at a minimum that:
(1) The patient agrees only to obtain scheduled medications from this particular prescribing practitioner;
(2) The patient agrees he or she will only fill those prescriptions at a single pharmacy which includes a pharmacy with more than one location;
(3) The patient agrees to notify the prescribing
practitioner within 72 hours of any emergency where he or she is prescribed
scheduled medication; and
(4) If the patient fails to honor the provisions of the narcotics contract, the prescribing practitioner may either terminate the provider-patient relationship or continue to treat the patient without prescribing a Schedule II opioid drug for the patient. Should the practitioner decide to terminate the relationship, he or she is required to do so pursuant to the provisions of this code and any rules promulgated hereunder. Termination of the relationship for the patient’s failure to honor the provisions of the contract is not subject to any disciplinary action by the practitioner’s licensing board; and
(5) If another physician is approved to prescribe to the patient.
(k) A pharmacist is not responsible for enforcing the provisions of this section and the Board of Pharmacy may not discipline a licensee if he or she fills a prescription in violation of the provisions of this section.
§16-54-5. Subsequent prescriptions; limitations.
(a) No fewer than six days After issuing the
initial Schedule II opioid drug prescription as set forth in §16-54-4 of
this code, the practitioner, after consultation with the patient, may issue a
subsequent prescription for an opioid a Schedule II opioid drug to
the patient if:
(1) The subsequent prescription would not be deemed an initial prescription pursuant to §16-54-4 of this code;
(2) The practitioner determines the prescription is necessary and appropriate to the patient’s treatment needs and documents the rationale for the issuance of the subsequent prescription; and
(3) The practitioner determines that issuance of the subsequent prescription does not present an undue risk of abuse, addiction, or diversion and documents that determination.
(b) Prior to issuing the subsequent Schedule II opioid drug prescription of the course of treatment, a practitioner shall discuss with the patient, or the patient’s parent or guardian if the patient is under 18 years of age, the risks associated with the Schedule II opioid drug being prescribed. This discussion shall include:
(1) The risks of addiction and overdose associated with a Schedule II opioid drugs and the dangers of taking Schedule II opioid drugs with alcohol, benzodiazepines, and other central nervous system depressants;
(2) The reasons why the prescription is necessary;
(3) Alternative treatments that may be available; and
(4) Risks associated with the use of the Schedule II
opioid drug being prescribed, specifically that opioids a
Schedule II opioid drug are highly addictive, even when taken as
prescribed, that there is a risk of developing a physical or psychological
dependence on the controlled substance Schedule II opioid drug,
and that the risks of taking more opioids than prescribed, or mixing sedatives,
benzodiazepines, or alcohol with opioids, can result in fatal respiratory
depression.
(c) The discussion as set forth in §16-54-5(b) of this code shall be included in a notation in the patient’s medical record.
§16-54-6. Ongoing treatment; referral to pain clinic or pain specialist.
(a) At the time of the issuance of the third prescription
for a prescription opioid Schedule II opioid drug the
practitioner shall consider referring the patient to a pain clinic or a pain
specialist. The practitioner shall discuss the benefits of seeking treatment
through a pain clinic or a pain specialist and provide him or her with an
understanding of any risks associated by choosing not to pursue that as an
option.
(b) If the patient declines to seek treatment from a pain
clinic or a pain specialist and opts to remain a patient of the practitioner,
and the practitioner continues to prescribe an opioid for pain a
Schedule II opioid drug as provided in this code, the practitioner shall:
(1) Note in the patient’s medical records that the patient knowingly declined treatment from a pain clinic or pain specialist;
(2) Review, at a minimum of every three months, the course of treatment, any new information about the etiology of the pain, and the patient’s progress toward treatment objectives and document the results of that review;
(3) Assess the patient prior to every renewal to determine whether the patient is experiencing problems associated with physical and psychological dependence and document the results of that assessment; and
(4) Periodically make reasonable efforts, unless clinically contraindicated, to either stop the use of the controlled substance, decrease the dosage, try other drugs or treatment modalities in an effort to reduce the potential for abuse or the development of physical or psychological dependence, and document with specificity the efforts undertaken.
§16-54-7. Exceptions.
(a) This article does not apply to a prescription
for a patient who is currently in active
treatment for cancer, receiving hospice care from a licensed hospice provider
or palliative care provider, or is a resident of a long-term care facility.
(b) This article does not apply to a patient or to
any medications that are being prescribed any medication for use in
the treatment of substance abuse or opioid dependence.
(c) This article does not apply to a patient being prescribed, or ordered, any medication in an inpatient setting at a hospital.
(b) (d) Notwithstanding the limitations
on the prescribing of a Schedule II opioid drug contained in §16-54-4 of this
code, a practitioner may prescribe an initial seven-day supply of an
opioid a Schedule II opioid drug to a
post-surgery patient immediately following a surgical procedure. Based upon
the medical judgment of the practitioner, a subsequent prescription may be
prescribed by the practitioner pursuant to the provisions of this code. Nothing
in this section authorizes a practitioner to prescribe any medication which he
or she is not permitted to prescribe pursuant to their practice act.
(c) (e) A practitioner who acquires
a patient after January 1, 2018, who is currently being prescribed an opioid
a Schedule II opioid drug from another practitioner shall be
is required to access the Controlled Substances Monitoring Program
Database as set forth in §60A-9-1 et seq. of this code. Any prescription would not be deemed an initial
prescription pursuant to the provisions of this section The practitioner shall otherwise treat
the patient as set forth in this code.
(d) (f) This article does not apply
to an existing practitioner-patient relationship established before January 1,
2018, where there is an established and current opioid treatment plan which is
reflected in the patient’s medical records.
§16-54-8. Treatment of pain.
(a) When patients seek a patient seeks treatment,
for any of the myriad conditions that cause pain, a health care
practitioner shall refer or prescribe to a patient any of the following
treatment alternatives, as is appropriate based on the practitioner’s
clinical judgment and the availability of the treatment, before starting a
patient on an opioid: physical therapy, occupational therapy, acupuncture,
massage therapy, osteopathic manipulation, chronic pain management program, and
chiropractic services, as defined in §30-16-3 of this code.
(b) Nothing in this section should be construed to require that all of the treatment alternatives set forth in §16-54-8(a) of this code are required to be exhausted prior to the patient receiving a prescription for an opioid.
(c) At a minimum, an insurance provider who offers an
insurance product in this state, the Bureau for Medical Services, and the
Public Employees Insurance Agency shall provide coverage for 20 total visits
per event of physical therapy, occupational therapy, osteopathic manipulation,
a chronic pain management program, and chiropractic services, as defined in
§30-16-3 of this code, when ordered or prescribed by a health care
practitioner. to treat conditions that cause chronic pain.
(d) A patient person may seek treatment
for physical therapy, occupational therapy, osteopathic manipulation, a
chronic pain management program, and chiropractic services, as defined in
§30-16-3 of this code, prior to seeking treatment from a health care practitioner.
and A health care practitioner referral is not required as a
condition of coverage by the Bureau for Medical Services the Public
Employees Insurance Agency, and any insurance provider who offers an insurance
product in this state. Any deductible, coinsurance, or copay required for any
of these services may not be greater than the deductible, coinsurance, or copay
required for a primary care visit.
(e) Nothing in this section precludes a practitioner from simultaneously prescribing an opioid and prescribing or recommending any of the procedures set forth in §16-54-8(a) of this code.
NOTE: The purpose of this bill is to clarify certain provisions within the Opioid Reduction Act 2018.
Strike-throughs indicate language that would be stricken from a heading or the present law and underscoring indicates new language that would be added.